IQVIA Holdings Inc. $IQV Stock: Robeco Institutional Asset Management B.V. Decreases Holdings

Robeco Institutional Asset Management B.V. cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 13.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 151,293 shares of the medical research company’s stock after selling 24,172 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in IQVIA were worth $40,675,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the business. Korea Investment CORP bought a new stake in shares of IQVIA during the 2nd quarter valued at about $13,918,000. Deutsche Bank AG bought a new stake in IQVIA in the second quarter worth approximately $143,074,000. BlackRock Inc. bought a new stake in IQVIA in the second quarter worth approximately $2,811,292,000. Congress Asset Management Co. bought a new stake in IQVIA in the third quarter worth approximately $24,560,000. Finally, Focus Partners Advisor Solutions LLC acquired a new position in IQVIA in the second quarter valued at approximately $976,000. 89.62% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. TD Cowen increased their price target on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. William Blair upgraded shares of IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. Weiss Ratings raised shares of IQVIA from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, September 24th. Finally, Barclays increased their target price on shares of IQVIA from $275.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $276.00.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the completion of the sale, the insider owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the sale, the insider owned 2,989 shares of the company’s stock, valued at $732,932.69. This trade represents a 15.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 15,581 shares of company stock valued at $3,796,021 over the last three months. 1.70% of the stock is currently owned by company insiders.

IQVIA Stock Up 0.6%

IQV stock opened at $278.25 on Friday. The stock’s 50 day simple moving average is $263.12 and its 200 day simple moving average is $215.98. The company has a market cap of $45.80 billion, a P/E ratio of 24.35, a price-to-earnings-growth ratio of 2.43 and a beta of 1.17. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $282.98.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. The firm had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. During the same quarter last year, the firm posted $2.81 earnings per share. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, research analysts expect that IQVIA Holdings Inc. will post 11.55 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.